Hexavest Inc. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 480,641 shares of the biopharmaceutical company’s stock, valued at approximately $32,645,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Hall Laurie J Trustee boosted its position in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC increased its stake in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares during the last quarter. Lombard Odier Transatlantic Limited Partnership increased its stake in Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 500 shares during the last quarter. First Bank & Trust purchased a new stake in Gilead Sciences during the fourth quarter worth about $140,000. Finally, Thomas J. Herzfeld Advisors Inc. purchased a new stake in Gilead Sciences during the fourth quarter worth about $143,000. 74.04% of the stock is currently owned by institutional investors.
Gilead Sciences, Inc. (NASDAQ:GILD) traded down 1.06% during mid-day trading on Friday, reaching $64.12. The company had a trading volume of 10,246,580 shares. The company has a market capitalization of $83.79 billion, a price-to-earnings ratio of 6.78 and a beta of 1.20. The firm’s 50 day moving average price is $65.64 and its 200-day moving average price is $69.18. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $88.85.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.18 by $0.02. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.66 billion. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. Equities research analysts anticipate that Gilead Sciences, Inc. will post $8.20 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Wednesday, June 14th. This represents a $2.08 annualized dividend and a dividend yield of 3.24%. Gilead Sciences’s dividend payout ratio is presently 21.99%.
A number of analysts have issued reports on GILD shares. Zacks Investment Research raised Gilead Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 11th. Jefferies Group LLC restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, April 6th. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $79.63 price objective for the company in a report on Tuesday, March 7th. Bank of America Corporation restated a “neutral” rating and set a $68.19 price objective (down previously from $76.00) on shares of Gilead Sciences in a report on Monday, March 13th. Finally, Mizuho lowered their target price on Gilead Sciences from $88.00 to $77.00 and set a “buy” rating for the company in a report on Wednesday, March 1st. Twelve analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $80.61.
In other news, Director John Francis Cogan sold 9,943 shares of the stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total transaction of $668,666.75. Following the transaction, the director now owns 47,562 shares of the company’s stock, valued at $3,198,544.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction dated Thursday, March 30th. The stock was sold at an average price of $67.48, for a total transaction of $337,400.00. Following the transaction, the executive vice president now directly owns 117,988 shares in the company, valued at approximately $7,961,830.24. The disclosure for this sale can be found here. Insiders have sold 88,276 shares of company stock valued at $5,932,578 over the last 90 days. Insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.